Literature DB >> 32761220

How much clotting is enough?

Laurent O Mosnier1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32761220      PMCID： PMC7414588          DOI： 10.1182/blood.2020006443

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  A hemophilia A mouse model for the in vivo assessment of emicizumab function.

Authors:  Stephen Ferrière; Ivan Peyron; Olivier D Christophe; Charlotte Kawecki; Caterina Casari; Vincent Muczynski; Amit Nathwani; Alexandre Kauskot; Peter J Lenting; Cécile V Denis
Journal:  Blood       Date:  2020-08-06       Impact factor: 22.113

2.  Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.

Authors:  Marilyn J Manco-Johnson; J Michael Soucie; Joan Cox Gill
Journal:  Blood       Date:  2017-02-09       Impact factor: 22.113

3.  A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.

Authors:  Takehisa Kitazawa; Tomoyuki Igawa; Zenjiro Sampei; Atsushi Muto; Tetsuo Kojima; Tetsuhiro Soeda; Kazutaka Yoshihashi; Yukiko Okuyama-Nishida; Hiroyuki Saito; Hiroyuki Tsunoda; Tsukasa Suzuki; Hideki Adachi; Taro Miyazaki; Shinya Ishii; Mika Kamata-Sakurai; Takeo Iida; Aya Harada; Keiko Esaki; Miho Funaki; Chifumi Moriyama; Eriko Tanaka; Yasufumi Kikuchi; Tetsuya Wakabayashi; Manabu Wada; Masaaki Goto; Takeshi Toyoda; Atsunori Ueyama; Sachiyo Suzuki; Kenta Haraya; Tatsuhiko Tachibana; Yoshiki Kawabe; Midori Shima; Akira Yoshioka; Kunihiro Hattori
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

4.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Authors:  Johannes Oldenburg; Johnny N Mahlangu; Benjamin Kim; Christophe Schmitt; Michael U Callaghan; Guy Young; Elena Santagostino; Rebecca Kruse-Jarres; Claude Negrier; Craig Kessler; Nancy Valente; Elina Asikanius; Gallia G Levy; Jerzy Windyga; Midori Shima
Journal:  N Engl J Med       Date:  2017-07-10       Impact factor: 91.245

Review 5.  New therapies for hemophilia.

Authors:  Angela C Weyand; Steven W Pipe
Journal:  Blood       Date:  2018-12-17       Impact factor: 22.113

6.  Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.

Authors:  Atsushi Muto; Kazutaka Yoshihashi; Minako Takeda; Takehisa Kitazawa; Tetsuhiro Soeda; Tomoyuki Igawa; Zenjiro Sampei; Taichi Kuramochi; Akihisa Sakamoto; Kenta Haraya; Kenji Adachi; Yoshiki Kawabe; Keiji Nogami; Midori Shima; Kunihiro Hattori
Journal:  Blood       Date:  2014-10-01       Impact factor: 22.113

7.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

Authors:  Johnny Mahlangu; Johannes Oldenburg; Ido Paz-Priel; Claude Negrier; Markus Niggli; M Elisa Mancuso; Christophe Schmitt; Victor Jiménez-Yuste; Christine Kempton; Christophe Dhalluin; Michael U Callaghan; Willem Bujan; Midori Shima; Joanne I Adamkewicz; Elina Asikanius; Gallia G Levy; Rebecca Kruse-Jarres
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

Review 8.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?

Authors:  Peter J Lenting; Cécile V Denis; Olivier D Christophe
Journal:  Blood       Date:  2017-10-17       Impact factor: 22.113

Review 9.  Emicizumab: A Review in Haemophilia A.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

10.  The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Authors:  Manuel Carcao; Carmen Escuriola-Ettingshausen; Elena Santagostino; Johannes Oldenburg; Ri Liesner; Beatrice Nolan; Angelika Bátorová; Saturnino Haya; Guy Young
Journal:  Haemophilia       Date:  2019-04-29       Impact factor: 4.287
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.